(BRUSSELS) Press Release Statement Report: European Commission Launch New Public/Private Corporation to Research, Combat New #COVID19 Variants #AceHealthDesk report

#AceHealthReport – Feb.17: On 17 February, the Commission presented the “HERA Incubator”, new European bio-defence preparedness plan against COVID-19 variants. The Incubator will bring together science, industry and public authorities and pull all available resources to prepare Europe for this challenge:

#Coronavirus Report: Safe #COVID19 vaccines for Europeans & Preparing for variants and securing additional vaccines from various sources’

On the same day, the Commission also secured 300 million more dosesof the proven safe and effective vaccine from Moderna, enlarging the EU’s vaccine portfolio to 2.6 billion of doses.

  • How do vaccines work?
  • How are vaccines developed, authorised and put on the market?
  • COVID-19 vaccines: making sure they are safe
  • Questions and answers about vaccines and vaccination

Securing doses of future vaccines

The European Commission has been negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with 6 promising vaccine developers, securing a portfolio of more than 2.6 billion doses. The Commission has also concluded exploratory talks with Novavax with a view to purchasing up to 200 million doses, and with Valneva with a view to purchase up to 60 million doses.

The Commission has so far given 3 conditional marketing authorisations for the vaccines developed by BioNTech and PfizerModerna and AstraZeneca following EMA positive assessment of their safety and efficacy.

  • 2.6 billion doses


Type of vaccine

Number of doses

(needed per person)


Type of vaccine

Number of doses

(needed per person)

Number of doses

(secured)StatusBioNTech and PfizermRNA2 doses600

millionApprovedModernamRNA2 doses460

millionApprovedCureVacmRNA2 doses405

millionDevelopment ongoingAstraZenecaadenovirus2 doses400

millionApprovedJohnson & Johnson/Janssen

Pharmaceuticalsadenovirus1 dose400 millionUnder evaluation by EMASanofi-GSKprotein2 doses300 millionDevelopment ongoing

Safety reports

The European Medicines Agency (EMA) released on 29 January its first safety update on a COVID-19 vaccine — Comirnaty, a vaccine produced by BioNTech and Pfizer. It concluded that safety data collected on Comirnaty use in vaccination campaigns was consistent with the known safety profile of the vaccine, and no new side effects were identified.

  • Reports of suspected severe allergic reaction have not identified new aspects regarding the nature of this known side effect.
  • No specific safety concern has been identified for vaccine use in frail elderly individuals. 
  • Its benefits in preventing COVID-19 continue to outweigh any risks, and there are no recommended changes regarding the use of the vaccine.

More information about this vaccine

Check the facts

Disinformation on the coronavirus is thriving. It is important that you get updated information from authoritative sources only. We suggest that you follow the advice of your public health authorities, and the websites of relevant EU and international organisations: the European Centre for Disease Control (ECDC ) and the World Health Organisation (WHO).

You can also help by not sharing unverified information that comes from dubious sources.

Fighting disinformation

The EU vaccine strategy

With the EU Vaccine Strategy, the EU is supporting efforts to accelerate the development and availability of safe and effective vaccines in a timeframe between 12 and 18 months, if not earlier. Delivering on this complex task requires running clinical trials in parallel with investing in production capacity to be able to produce millions, or even billions, of doses of a successful vaccine.

The EU vaccine strategy

Hear from the experts

Peter Piot, virologist

Peter Piot, virologist

Dr Frank Ulrich Montgomery,
President of the Standing Committee of European Doctors

Videos of experts on a COVID-19 vaccine

Hear from the people

Borislava Ananieva, transplant patient


European Centre for Disease Prevention and Control

European Medicines Agency

#AceHealthDesk report ………..Published: Feb.17: 2021:

Editor says #AceNewsDesk reports by https://t.me/acenewsdaily and all our posts, also links can be found at here for Twitter and Live Feeds https://acenewsroom.wordpress.com/ and thanks for following as always appreciate every like, reblog or retweet and free help and guidance tips on your PC software or need help & guidance from our experts AcePCHelp.WordPress.Com